Abstract
Pathologic conditions resulting from excessive bone destruction include osteoporosis, rheumatoid arthritis, metastases, periprosthetic osteolysis, cherubism, and others. A scarcity of molecular targets in bone has thwarted the development of drugs to combat these conditions. Nuclear factor of activated T-cells (NFAT) is a master regulator of osteoclastogenesis and is induced by RANKL. The immunosuppressive drugs, Cyclosporin A and Tacrolimus, inhibit osteoclast formation by targeting the NFAT/calcineurin pathway. These NFAT inhibitors should be considered in the treatment of osteoclastic hyper-resorptive syndromes.
Similar content being viewed by others
References
Day CJ, Kim MS, Lopez CM et al (2005) NFAT expression in human osteoclasts. J. Cell Biochem 95(1):17–23
Lietman SA, Yin L, Levine MA (2008) SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem. Biophys. Res. Commun 371(4):644–648
Clipstone NA, Crabtree GR (1992) Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 357(6380):695–697
Beals CR, Clipstone NA, Ho SN et al (1997) Nuclear localization of NFATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Genes Dev 11(7):824–834
Takayanagi H, Kim S, Koga T et al (2002) Induction and activation of the transcription factor NFATc1(NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3:889–901
Hirotani H, Tuohy NA, Woo JT et al (2004) The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem 279(14):13984–13992
Asagiri M, Sato K, Usami T et al (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med 202:1261–1269
Ishida N, Hayashi K, Hoshijima M et al (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem 277(43):41147–41156
Komarova SV, Pereverzev A, Shum JW et al (2005) Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proc. Natl. Acad. Sci. U S A 102(7):2643–2648
Yeo H, Beck LH, Thompson SR et al (2007) Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. J. Biol. Chem 282(48):35318–35327
Sun L, Peng Y, Zaidi N et al (2007) Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am. J. Physiol. Renal Physiol 292(1):F285–F291
Kino T, Hatanaka H, Hashimoto M et al (1987) FK-506, a novel immunosuppressant isolated from a streptomyces. 1. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 40(9):1249–1255
Miyazaki M, Fujikawa Y, Takita C et al (2007) Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun orMITF in rheumatoid arthritis. Clin. Rheumatol 26(2):231–239
Timmerman LA, Clipstone NA, Ho SN et al (1996) Rapid shuttling of NFAT in discrimination of Ca2+ signals and immunosuppression. Nature 383:837–840
Day CJ, Kim MS, Stephens SRJ et al (2004) Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J. Cell Biochem 91:303–315
Epstein S, Shane E, Bilezikian JP (1995) Organ transplantation and osteoporosis. Curr. Opin. Rheumatol 7(3):255–261
Yamanaka Y, Abu-Amer W, Foglia D et al (2008) NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis. J. Orthop. Res 26(12):1577–1584
Author information
Authors and Affiliations
Corresponding author
Additional information
The author certifies that he has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.
Rights and permissions
About this article
Cite this article
McMahon, M.S. Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?. HSS Jrnl 5, 159–160 (2009). https://doi.org/10.1007/s11420-009-9115-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11420-009-9115-x